CpG Blocks Immunosuppression by Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice

Clinical Cancer Research, 2011, doi: 10.1158/1078-0432.CCR-10-2672, published on 13.01.2011
Clinical Cancer Research, online article
Purpose: The Toll-like receptor (TLR) 9 ligand CpG has been used successfully for the immunotherapy of cancer. Chronic CpG application in tumor-free hosts leads, however, to the expansion of myeloid-derived suppressor cells (MDSC), which can cause T-cell suppression and may thus hamper the development of an effective immune response. Here, we investigated the effect of TLR9 activation on the function of MDSC in tumor-bearing mice.

TU München
Helmholtz München
MPI of Neurobiology
MPI of Biochemistry